Literature DB >> 27513883

Polycystic ovary syndrome and psychiatric disorders: Co-morbidity and heritability in a nationwide Swedish cohort.

Carolyn E Cesta1, Mattias Månsson2, Camilla Palm3, Paul Lichtenstein3, Anastasia N Iliadou3, Mikael Landén4.   

Abstract

Polycystic ovary syndrome (PCOS) is an endocrine disorder affecting 5-15% of reproductive-aged women and characterized by high levels of circulating androgens. Given that androgens have been implicated in the aetiology of several psychiatric disorders, it was hypothesized that women with PCOS have high risk for psychiatric comorbidity. We aimed to investigate this risk amongst women with PCOS, as well as in their siblings, to elucidate if familial factors underlie any potential associations. Using the Swedish national registers, we identified all women diagnosed with PCOS between 1990 and 2013 (n=24,385), their full-siblings (n=25,921), plus matched individuals (1:10/100) from the general population and their full-siblings. Psychiatric disorder diagnoses were identified including schizophrenia, bipolar disorder, depressive and anxiety disorders, eating disorders, personality and gender identity disorder, autism spectrum disorder (ASD), attention-deficit hyperactivity disorder (ADHD), tics, attempted and completed suicide. Odds ratios (OR) and 95% confidence intervals (CI) were estimated using conditional logistic regression and adjusted ORs (AOR) were determined by adjustment for comorbid psychiatric disorders. Overall, women with PCOS had an increased odds of having at least one psychiatric disorder (OR=1.56 [95CI%, 1.51-1.61]). Crude ORs showed associations with nearly all psychiatric disorders included in this study. Following adjustment for comorbid psychiatric disorders, women with PCOS were still at a significantly increased risk for bulimia, schizophrenia, bipolar disorder, depressive and anxiety disorders, personality disorders, with the highest AORs for ASD (AOR=1.55 [95%CI, 1.32-1.81]) and tics (AOR=1.65 [95%CI, 1.10-2.47]). Significantly higher AORs were found for ASD in both brothers and sisters of women with PCOS, and for depressive, anxiety, and schizophrenia spectrum disorders in the sisters only. Notably, the crude ORs for attempted suicide were 40% higher in women with PCOS and 16% higher in their unaffected sisters. However, the AORs were greatly attenuated indicating that underlying psychiatric comorbidity is important for this association. Women with PCOS had higher risks for a range of psychiatric disorders not shown before. Elevated risk in their siblings suggests shared familial factors between PCOS and psychiatric disorders. This study is an important first step towards identifying the underlying mechanisms for risk of psychiatric disorders in women with PCOS. Health professionals treating women with PCOS should be aware that these patients - as well as their family members - are important targets for mental health care.
Copyright © 2016 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Androgens; Epidemiology; Polycystic ovary syndrome; Psychiatric disorders; Sibling analysis

Mesh:

Year:  2016        PMID: 27513883     DOI: 10.1016/j.psyneuen.2016.08.005

Source DB:  PubMed          Journal:  Psychoneuroendocrinology        ISSN: 0306-4530            Impact factor:   4.905


  42 in total

Review 1.  Ultrasound-guided transvaginal ovarian needle drilling for clomiphene-resistant polycystic ovarian syndrome in subfertile women.

Authors:  Jing Zhang; Liulin Tang; Linglingli Kong; Taixiang Wu; Liangzhi Xu; Xin Pan; Guan J Liu
Journal:  Cochrane Database Syst Rev       Date:  2019-07-31

Review 2.  The International College of Neuro-Psychopharmacology (CINP) Treatment Guidelines for Bipolar Disorder in Adults (CINP-BD-2017), Part 2: Review, Grading of the Evidence, and a Precise Algorithm.

Authors:  Konstantinos N Fountoulakis; Lakshmi Yatham; Heinz Grunze; Eduard Vieta; Allan Young; Pierre Blier; Siegfried Kasper; Hans Jurgen Moeller
Journal:  Int J Neuropsychopharmacol       Date:  2017-02-01       Impact factor: 5.176

Review 3.  Hyperandrogenic origins of polycystic ovary syndrome - implications for pathophysiology and therapy.

Authors:  David H Abbott; Daniel A Dumesic; Jon E Levine
Journal:  Expert Rev Endocrinol Metab       Date:  2019-02-15

4.  Increased odds of disordered eating in polycystic ovary syndrome: a systematic review and meta-analysis.

Authors:  Iris Lee; Laura G Cooney; Shailly Saini; Mary D Sammel; Kelly C Allison; Anuja Dokras
Journal:  Eat Weight Disord       Date:  2018-06-26       Impact factor: 4.652

Review 5.  Depression and Anxiety in Polycystic Ovary Syndrome: Etiology and Treatment.

Authors:  Laura G Cooney; Anuja Dokras
Journal:  Curr Psychiatry Rep       Date:  2017-09-20       Impact factor: 5.285

Review 6.  Animal Models to Understand the Etiology and Pathophysiology of Polycystic Ovary Syndrome.

Authors:  Elisabet Stener-Victorin; Vasantha Padmanabhan; Kirsty A Walters; Rebecca E Campbell; Anna Benrick; Paolo Giacobini; Daniel A Dumesic; David H Abbott
Journal:  Endocr Rev       Date:  2020-07-01       Impact factor: 19.871

7.  Maternal polycystic ovarian syndrome in autism spectrum disorder: a systematic review and meta-analysis.

Authors:  Maria Katsigianni; Vasilios Karageorgiou; Irene Lambrinoudaki; Charalampos Siristatidis
Journal:  Mol Psychiatry       Date:  2019-03-13       Impact factor: 15.992

Review 8.  In utero Androgen Excess: A Developmental Commonality Preceding Polycystic Ovary Syndrome?

Authors:  David H Abbott; Marissa Kraynak; Daniel A Dumesic; Jon E Levine
Journal:  Front Horm Res       Date:  2019-09-09       Impact factor: 2.606

Review 9.  Epigenetic inheritance of polycystic ovary syndrome - challenges and opportunities for treatment.

Authors:  Elisabet Stener-Victorin; Qiaolin Deng
Journal:  Nat Rev Endocrinol       Date:  2021-07-07       Impact factor: 43.330

10.  Anxiety Disorders Among Women: A Female Lifespan Approach.

Authors:  Liisa Hantsoo; C Neill Epperson
Journal:  Focus (Am Psychiatr Publ)       Date:  2017-04-10
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.